What is the ROCE (Return on Capital Employed) of Amgen this year?
The ROCE of Amgen is 1.31 undefined this year.
Amgen ROCE 2024
Amgen ROCE
1.31
Ticker
AMGN
ISIN
US0311621009
WKN
867900
In 2024, Amgen's return on capital employed (ROCE) was 1.31, a -52.67% increase from the 2.77 ROCE in the previous year.
Amgen Aktienanalyse
What does Amgen do?
Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Amgen revenue by segment
In the annual report of the Amgen share (US0311621009, 867900, AMGN), it breaks down its revenues into 2 segments: 1. Human Therapeutics, 2. Other. The Amgen stock (WKN: 867900, ISIN: US0311621009, Ticker Symbol: AMGN) is a leading investment for investors interested in participating in the Health Care sector.
95 % Human Therapeutics
5 % Other
ROCE Details
Unraveling Amgen's Return on Capital Employed (ROCE)
Amgen's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Amgen's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Amgen's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Amgen’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Amgen stock
How has the ROCE (Return on Capital Employed) of Amgen developed compared to the previous year?
The ROCE of Amgen has increased by -52.67% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Amgen?
A high Return on Capital Employed (ROCE) indicates that Amgen has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Amgen?
A low ROCE (Return on Capital Employed) can indicate that Amgen has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Amgen impact the company?
An increase in the ROCE of Amgen can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Amgen affect the company?
A decrease in ROCE of Amgen can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Amgen?
Some factors that can affect Amgen's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Amgen so important for investors?
The ROCE of Amgen is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Amgen take to improve the ROCE?
To improve the ROCE, Amgen can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Amgen pay?
Over the past 12 months, Amgen paid a dividend of 8.52 USD . This corresponds to a dividend yield of about 2.67 %. For the coming 12 months, Amgen is expected to pay a dividend of 14.1 USD.
What is the dividend yield of Amgen?
The current dividend yield of Amgen is 2.67 %.
When does Amgen pay dividends?
Amgen pays a quarterly dividend. This is distributed in the months of March, June, September, December.
How secure is the dividend of Amgen?
Amgen paid dividends every year for the past 19 years.
What is the dividend of Amgen?
For the upcoming 12 months, dividends amounting to 14.1 USD are expected. This corresponds to a dividend yield of 4.42 %.
In which sector is Amgen located?
Amgen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Amgen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Amgen from 12/9/2024 amounting to 2.25 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.
When did Amgen pay the last dividend?
The last dividend was paid out on 12/9/2024.
What was the dividend of Amgen in the year 2023?
In the year 2023, Amgen distributed 7.76 USD as dividends.
In which currency does Amgen pay out the dividend?
The dividends of Amgen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Amgen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von Amgen
Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
